![]() ![]() Therefore, these cases including equivalent pathophysiology are enough to make a comparable category as “symptomatic hypersomnia”. However, symptomatic hypersomnia had similar severity of hypersomnolence symptoms to symptomatic narcolepsy. Currently, symptomatic hypersomnia cases with intermediate orexin levels or short sleep latency (< 8 min) without SOREMPs were not classified as a specific entity. We proposed these latter cases as a novel category of “symptomatic hypersomnia”. ![]() We identified that 32 symptomatic narcolepsy and 14 cases of symptomatic hypersomnolence with intermediate CSF orexin levels. From these results, we found that it is difficult to estimate orexin concentration from subjective symptoms and PSG/MSLT findings. Significant differences were not found between orexin levels and the existence of cataplexy, SOREMPs, and short sleep latency among three hypersomnolence groups. Causative diseases of symptomatic narcolepsy cases consist of immune-mediated demyelinating disorders (34%) and neurodegenerations (19%), whereas those of symptomatic hypersomnia are immune-mediated demyelinating disorders (43%) and encephalopathies (14%). ResultĪmong the 182 cases with clinical hypersomnolence, there were 32 cases of symptomatic narcolepsy (16%) and 14 cases of symptomatic hypersomnia (8%). We compared symptoms (excessive daytime sleepiness and cataplexy) and objective measures (mean sleep latency and number of SOREMPs in MSLT) among the three groups, attempting to characterize the “symptomatic hypersomnia” group. Short sleep latency (< 8 min) without SOREMPs should be observed on MSLT when performed. We defined “symptomatic hypersomnia” for hypersomnolence cases with intermediate CSF orexin levels. Therefore, we subdivided these cases into three groups according to CSF orexin levels, low orexin group (≤ 110 pg/ml), intermediate orexin group (110–200 pg/ml), and normal orexin group (> 200 pg/ml). We measured over 2500 cases including 182 cases suspected of symptomatic narcolepsy/hypersomnolence. Currently, our laboratory handles with almost all the CSF samples from Asian countries for determining orexin levels. MethodsĪlthough orexin-deficient symptomatic narcolepsy has been reported worldwide, facilities that are capable of measuring orexin are still limited. Therefore, we reevaluated the previously reported cases to make the concept of disease to the group in which the orexin concentration is intermediate. However, we have experienced the cases that show symptoms similar to narcolepsy, complaining of pathological sleepiness even in cases with intermediate orexin levels (110–200 pg/ml). Symptomatic narcolepsy is characterized as low orexin (hypocretin) levels (≤ 110 pg/ml) due to neurological diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |